Loading…
Rani Therapeutics Holdings, Inc. is projected to rise to $0.7176 by 2027, a +4% move from its current price of $0.6872. RANI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.6627 | $0.6876 | $0.7135 | +0.06% |
| Jul 15 | $0.653 | $0.688 | $0.7249 | +0.12% |
| Jul 16 | $0.6457 | $0.6884 | $0.7339 | +0.18% |
| Jul 17 | $0.6397 | $0.6888 | $0.7417 | +0.23% |
| Jul 18 | $0.6346 | $0.6892 | $0.7486 | +0.29% |
| Jul 19 | $0.6299 | $0.6896 | $0.755 | +0.35% |
| Jul 20 | $0.6258 | $0.69 | $0.7609 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6258 | $0.69 | $0.7609 | +0.41% |
| Week 2 | $0.6034 | $0.6929 | $0.7956 | +0.82% |
| Week 3 | $0.5873 | $0.6957 | $0.8241 | +1.24% |
| Week 4 | $0.5745 | $0.6986 | $0.8494 | +1.65% |
| Week 5 | $0.5637 | $0.7014 | $0.8728 | +2.07% |
| Week 6 | $0.5543 | $0.7043 | $0.8949 | +2.49% |
| Week 7 | $0.546 | $0.7072 | $0.916 | +2.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company focused on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Rani Therapeutics was founded in 2012 and is headquartered in San Jose, California. The company has collaborations to expand its oral delivery platform, including a collaboration with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity, and a collaboration with Chugai Pharmaceutical Co., Ltd.
to commercialize the Chugai Product combining Chugai’s Compound for hemophilia with the RaniPill HC oral delivery device for use in humans.
Rani Therapeutics Holdings, Inc. (RANI) is in Healthcare, with a current price of $0.693 and a market cap of $95.28M, and it is ranked 4231 by market capitalization. The stock is assessed with near-term dynamics that are generally neutral, while the longer horizon shows potential upside as the forecast progresses into bullish territory in later years.
A major floor 25.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 38.5% above — a clean break opens room to run.
A major ceiling 100.8% above — clearing it would confirm fresh momentum.
Key RANI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RANI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.716 | Sell | $0.7097 | Sell |
| MA 10 | $0.738 | Sell | $0.7298 | Sell |
| MA 20 | $0.7527 | Sell | $0.7622 | Sell |
| MA 50 | $0.8702 | Sell | $0.8462 | Sell |
| MA 100 | $0.9824 | Sell | $0.9511 | Sell |
| MA 200 | $1.19 | Sell | $1.07 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.26 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -174.36 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -9.01 | Sell |
| Bollinger %B (20,2) | -0.02 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.77 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 27.61 | Buy |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.68 | Buy |
| ADX (14) | 21.43 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture shows a neutral stance. RSI(14) is 30, with the 50-day simple moving average at $0.8777 and the 200-day simple moving average at $1.19. The stock trades with support at $0.693 and resistance at $0.952, and the 30-day range runs from $0.5354 to $0.8971. Annualized volatility stands around 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.687 | $0.6872 | $0.9057 | 0% | Neutral | |
| $0.5526 | $0.7176 | $0.9964 | +4% | Neutral | |
| $0.5002 | $0.6756 | $0.9838 | -2% | Neutral | |
| $0.4937 | $0.6891 | $1.04 | 0% | Neutral | |
| $0.445 | $0.6396 | $0.9967 | -7% | Neutral | |
| $0.4104 | $0.606 | $0.9699 | -12% | Neutral | |
| $0.5334 | $0.8078 | $1.32 | +18% | Neutral | |
| $0.5683 | $0.8814 | $1.48 | +28% | Bullish | |
| $0.54 | $0.8569 | $1.46 | +25% | Bullish | |
| $0.5657 | $0.9177 | $1.60 | +34% | Bullish | |
| $0.6823 | $1.23 | $2.30 | +78% | Bullish | |
| $0.8002 | $1.73 | $3.62 | +152% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.687 | $0.6872 | $0.8362 | +0.00% |
| August 2026 | $0.6099 | $0.7267 | $0.894 | +5.75% |
| September 2026 | $0.6026 | $0.7249 | $0.9051 | -0.25% |
| October 2026 | $0.5722 | $0.694 | $0.8773 | -4.26% |
| November 2026 | $0.5678 | $0.6935 | $0.8859 | -0.07% |
| December 2026 | $0.5712 | $0.7023 | $0.9057 | +1.27% |
Click any year to see its month-by-month RANI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RANI is projected to trade between $0.687 and $0.9057, averaging $0.6872 — a potential gain of 0% from today's $0.6872. A consolidation phase looks the most probable path here.
Rani Therapeutics Holdings, Inc.'s 2027 outlook centres on $0.7176, within a $0.5526 to $0.9964 range. That is up +4% on the projected 2026 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2028, RANI could reach as high as $0.9838, with a base case around $0.6756 and support toward $0.5002 — roughly -2% from $0.6872. A consolidation phase looks the most probable path here.
Expect RANI to range from $0.4937 to $1.04 through 2029. The $0.6891 average target implies a 0% move from current prices. That is up +2% on the projected 2028 average. Price action looks broadly range-bound.
The RANI price prediction for 2030 points to an average of $0.6396 (low $0.445, high $0.9967) — a potential decline of -7% on today's $0.6872. A consolidation phase looks the most probable path here.
In 2031, RANI is projected to trade between $0.4104 and $0.9699, averaging $0.606 — a potential decline of -12% from today's $0.6872. That is -5% versus the projected 2030 average. Price action looks broadly range-bound.
Rani Therapeutics Holdings, Inc.'s 2032 outlook centres on $0.8078, within a $0.5334 to $1.32 range. That is up +33% on the projected 2031 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, RANI could reach as high as $1.48, with a base case around $0.8814 and support toward $0.5683 — roughly +28% from $0.6872. Momentum favours further upside here.
Expect RANI to range from $0.54 to $1.46 through 2034. The $0.8569 average target implies a +25% move from current prices. That is -3% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The RANI price prediction for 2035 points to an average of $0.9177 (low $0.5657, high $1.60) — a potential gain of +34% on today's $0.6872. Momentum favours further upside here.
In 2040, RANI is projected to trade between $0.6823 and $2.30, averaging $1.23 — a potential gain of +78% from today's $0.6872. That is up +34% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Rani Therapeutics Holdings, Inc.'s 2050 outlook centres on $1.73, within a $0.8002 to $3.62 range. That is up +41% on the projected 2040 average. That marks a +152% change versus current levels. Momentum favours further upside here.
Investing $1,000 in RANI today (≈ 1,455.180442 RANI) could be worth
$2,518.32
+$1,518.32 (+152%) by 2050 · US Dollar
Based on the average projected RANI price of $1.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RANIwould be worth at today's price.
$1,000 invested in RANI on Jul 10, 2025 (≈ 1,515.151455 RANI) would be worth
$1,041.21
+$41.21 (+4.1%) today · 1.04× · US Dollar
Based on a RANI entry price of $0.66 vs. today's $0.6872.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.771 | $891.31 | -10.9% |
| 1 month ago | $0.783 | $877.65 | -12.2% |
| 3 months ago | $0.74 | $928.65 | -7.1% |
| 6 months ago | $1.49 | $461.21 | -53.9% |
| 1 year ago | $0.66 | $1,041.21 | +4.1% |
| All time (4.9y) ago | $11 | $62.47 | -93.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RANI forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $157.34M
The multi-year forecast presents a cautious start in the near term, with years 2026 to 2032 showing neutral sentiment and modest price activity around the current level. The average price in 2026 is forecast at $0.693, with a max of $0.9189 and a min of $0.693, yielding 0% ROI. By 2033 the outlook becomes bullish, with an average of $0.8884 and a max of $1.52 (ROI 28.2%).
In 2034 the average is $0.8642 with a max of $1.50 (ROI 24.7%), and in 2035 the average climbs to $0.9249 with a max of $1.64 (ROI 33.5%). The up‑trend continues through 2040 (avg $1.25, max $2.39, ROI 79.7%) and into 2050 (avg $1.72, max $3.70, ROI 148.8%). These figures reflect a shift from neutral to bullish sentiment over time, with the most pronounced upside captured in the 2040–2050 horizon.
Drivers and risks are not specified in the data; these figures are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $0.6348, with a minimum of $0.435 and a maximum of $1.00, resulting in an expected ROI of -8.4% and a neutral sentiment.
The forecast indicates mixed outcomes: near term (2026–2032) is neutral with some years showing negative ROI (e.g., 2030 -8.4%, 2031 -12.7%). Longer horizons turn bullish from 2033 onward, with positive ROIs up to 148.8% by 2050, but these are estimates and not guarantees.
Yes. The forecast maximums show $1.52 in 2033, $1.50 in 2034, and $1.64 in 2035, with higher tops in later years (e.g., $2.39 in 2040 and $3.70 in 2050). These are scenario-based estimates, not guarantees.
For 2032, the min is $0.5279, the average is $0.815, and the max is $1.36, with a ROI of 17.6% and neutral sentiment.
Current price is $0.693 and market cap is $95.28M.
Rani Therapeutics Holdings, Inc. Community Discussion
0Share your Rani Therapeutics Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.